Raymond James & Associates Decreases Stake in Profound Medical Corp. (NASDAQ:PROF)

Raymond James & Associates reduced its position in Profound Medical Corp. (NASDAQ:PROF) by 3.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,693 shares of the company’s stock after selling 2,038 shares during the period. Raymond James & Associates owned 0.27% of Profound Medical worth $558,000 at the end of the most recent quarter.

Separately, MTM Investment Management LLC lifted its position in shares of Profound Medical by 8.2% in the third quarter. MTM Investment Management LLC now owns 19,875 shares of the company’s stock worth $203,000 after buying an additional 1,500 shares in the last quarter. 47.86% of the stock is currently owned by hedge funds and other institutional investors.

Profound Medical Trading Up 0.5 %

Shares of NASDAQ PROF opened at $8.03 on Friday. The business’s 50 day moving average is $8.30 and its two-hundred day moving average is $8.78. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.58 and a quick ratio of 5.48. Profound Medical Corp. has a 1-year low of $7.11 and a 1-year high of $15.49. The stock has a market capitalization of $196.17 million, a P/E ratio of -5.95 and a beta of 0.80.

Profound Medical (NASDAQ:PROF) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Profound Medical had a negative return on equity of 70.18% and a negative net margin of 396.85%. The company had revenue of $2.01 million for the quarter, compared to the consensus estimate of $1.90 million. As a group, research analysts expect that Profound Medical Corp. will post -1.17 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners decreased their target price on Profound Medical from $14.25 to $12.75 and set a “buy” rating on the stock in a research report on Thursday, January 4th.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.